Zemdri: Withdrawal of the marketing authorisation application


Cipla Europe NV withdrew its application for a marketing authorisation of Zemdri for the treatment of complicated urinary tract infection.

The company withdrew the application on 16 June 2020.

Key facts

Product number
Active substance
  • Plazomicin (sulfate)
Date of withdrawal
Company making the application
Cipla Europe NV
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating